3LEGRYS V A.The use of high sensitivity C-reactive protein in accessing the risk for coronary heart disease[J].Clin Lab Sci,2001,14(4):243-246.
4LIBBY P,RIDKER P M,MSSERI A.Inflammation and atheroslerosis[J].Circulation,2002,105(9):1135-1143.
5LIBBY P.What have we learned about the biology of atherosclerosis? The role of inflammation[J].Am J Cardiol,2001,88(7B):3J-6J.
6DATE H,IMAMURA T,SUMI T,et al.Effects of interleukin-6 produced in coronary circulantion on produciton of C-reactive protein and coronary microvascular resistance[J].Am J Cardiol,2005,95(7):849-852.
7ARROYO ESPLIGUERO R,AVANZAS P,COSIN SALES J,et al.C-reactive protein elevation and disease activity in patiens with coronary artery disease[J].Eur Heart J,2004,25(5):401-408.
8RIDKER P M.C-reactive protein:eighty years from discovery to emergence as a major risk marke for cardiovascular disease[J].Clin Chem,2009,55(2):209-215.
9RIDKER P M,RIFAI N,CLEARFIELD M,et al.Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[J].N Engl J Med,2001,344(26):1959-1965.
10RIDKER P M,DANIELSON E,FONSECA F A,et al.Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin:a prospective study of the JUPITER trial[J].Lancet,2009,373(9670):1175-1182.
